Can your genes predict prostate Cancer's next move?

NCT ID NCT05810467

Recruiting now Knowledge-focused Sponsor: Institute of Cancer Research, United Kingdom Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 200 men with low-risk prostate cancer who are on active surveillance (monitoring instead of immediate treatment). Researchers want to see if men with a higher genetic risk for prostate cancer are more likely to have their cancer progress over time. The goal is to better understand who can safely stay on surveillance and who may need treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors better predict which men with low-risk prostate cancer can safely avoid treatment and which need closer monitoring.
What could go wrong: This is an observational study, not a treatment trial. It will not directly improve outcomes for participants, and results may take years to influence clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Institute of Cancer Research and Royal Marsden Hospital
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
North Bristol NHS Trust
NOT_YET_RECRUITING

Bristol, BS10 5NB, United Kingdom
The Royal Marsden Hospital
RECRUITING

London, SW3 6JJ, United Kingdom
The Royal Marsden Hospital
RECRUITING

Sutton, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.